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Case Report
INTRODUCTION
Calciphylaxis is an uncommon necrotizing skin condi-
tion that mainly affects patients with chronic renal 
failure and often leads to fatal consequences. It is char-
acterized by excessive calcification of soft tissue and 
small arteries, leading to ischemic ulceration of the 
skin [1]. The prevalence of calciphylaxis among the 
dialysis population may be as high as 4%, possibly as 
a result of the greater use of calcium salts and vitamin 
D for the treatment of hyperphosphatemia in these pa-
tients [2,3]. Chronic renal failure, hyperparathyroidism, 
hypercalcemia, and hyperphosphatemia often trigger the 
precipitation of calcium-phosphate crystals in the arte-
rioles of the dermis and soft tissues, leading to ischemia 
and skin ulcerations. The diagnosis of calciphylaxis is 
mainly clinical and skin biopsy is infrequently done 
because of the risk of poor healing and secondary infec-
tions. Despite aggressive treatment regimens, mortality 
continues to be high.
We report the case of a 44-year-old female end-stage 
renal disease patient with multiple non-healing skin 
ulcers secondary to calciphylaxis complicated with 
refractory infections including Candida tropicalis 
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fungemia, vancomycin-resistant enterococcus and 
Acinetobacter baumannii wound infections.
CASE REPORT
A 44-year-old obese female (body mass index, 32) with 
end-stage renal disease secondary to diabetes mellitus 
and uncontrolled hypertension presented to our emer-
gency room with a 10-day history of multiple painful 
and rapidly progressing skin necrotic ulcers. Her 
medical history included peritoneal dialysis for 4 years 
(two exchanges with 3-hour dwell times daily) and 
obstructive sleep apnea with no other comorbidities.
Upon examination, a 20 × 4.5 cm ulcer covered with 
blackish eschar with gangrenous fibrinopurulent mate-
rial was found on her left lower extremity. Additional 
lesions were found on the left and right buttocks, left 
lateral hip, left proximal and distal leg, left anterior and 
lateral leg, and right lateral leg (Figure 1). All the lesions 
were either violaceous or were covered with leathery 
black eschar. The patient denied any recent illness or 
previous antibiotic use for the last 3 months.
She was febrile with a temperature of 38.5°C; heart 
rate was 96 beats per minute and respiratory rate was 
13 breaths per minute. Her white blood cell count was 
elevated (17.8 × 109/L). Calcium was 8.5 mg/dL (normal, 
8.6–10.5 mg/dL), phosphorus was 5.5 mg/dL (normal, 
2.4–5.0 mg/dL), calcium phosphorus byproduct was 
46.75 (normal, 20.6–52.5 mg2/dL2), and parathyroid 
hormone was 75.4 pg/mL (normal, 10–65 pg/mL). Her 
distal pulses were palpable. Before this current presen-
tation, her phosphorus level had been slightly elevated in 
the clinic and she was taking calcium salts and vitamin D 
once daily.
Blood and wound cultures were taken. The blood 
culture was positive for C. tropicalis. The wound culture 
was positive for A. baumannii and vancomycin-resistant 
enterococci. Noncontrast computed tomography of the 
patient’s lower extremities revealed diffuse calcification 
of the small and medium sized arteries. Posterior and 
anterior tibial arteries were affected and did not show 
any evidence of necrotizing fasciitis, which has a rapid 
course of progression.
She had local debridement and wound care. She was 
then put on vancomycin and piperacillin/tazobactam. 
After the blood and wound culture results were obtained, 
treatment was switched to fluconazole, tigecycline and 
cefepime for a total duration of 2 weeks. Her left leg 
was amputated below the knee.
Pathology revealed necrosis of the dermis and sub-
cutaneous fat, endovascular fibroplastic intimal prolif-
eration, narrowing and occlusion of the arterioles from 
medial calcification, and thrombi of calcium (Figures 2 
and 3). Ophthalmological report revealed that C. tropicalis 
had not spread to the eye. Echocardiography showed no 
vegetations. She was discharged to a long-term care 
facility 5 days postoperatively.
Figure 1. A 20-cm blackish necrotic eschar-covered lesion on the 
left lower extremity.
Figure 3. Note the thickening of the arterial wall (black arrow) and 
infiltration of neutrophils within and adjacent to the wall of the 
artery (white arrow).
Figure 2. Calcium deposition (black arrow) within a small artery in 
the septum of subcutaneous fat (hematoxylin & eosin, 40×).
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The 1-month follow-up of the patient at the long-
term care facility revealed worsening multiple non-
healing skin ulcers. She was treated with hyperbaric 
oxygen, but there was no improvement. Parathyroidec-
tomy was not seriously considered since her parathyroid 
hormone was not extremely elevated. The patient devel-
oped sepsis. Transesophageal echocardiography ruled 
out infective endocarditis. Her clinical condition dete-
riorated and she died a few days later.
DISCUSSION
Calciphylaxis is a rare but serious disease. It is a syndrome 
of vascular calcification, thrombosis and skin necrosis. 
It is seen almost exclusively in patients with stage 5 
chronic kidney disease. It results in chronic non-healing 
wounds and is usually fatal.
Calciphylaxis is characterized by systemic medial 
calcification of the arteries and by small vessel mural 
calcification with or without endovascular fibrosis, 
extravascular calcification and vascular thrombosis, 
leading to tissue ischemia and hence skin necrosis.
Non-healing skin ulcers are the most frequent der-
matological manifestation of calciphylaxis [4]. The term 
calciphylaxis was coined by Selye 1962 [5]. In 1960, 
tissue calcification was observed in patients with end-
stage renal failure on dialysis [6]. Calciphylaxis can 
occur in hemodialysis patients, continuous ambulatory 
peritoneal dialysis patients, and even in predialysis 
patients [7,8]. One percent to 4% of hemodialysis patients 
may present with calciphylaxis [9]. The risk factors for 
calciphylaxis include female sex [10], diabetes [7,8,11], 
warfarin use and protein C or S deficiency, iron overload 
[11], and trauma to the skin including subcutaneous 
injections of heparin or insulin [11]. Poor metabolic 
control of calcium and phosphate with secondary or ter-
tiary hyperparathyroidism and a high Ca × PO4 product 
have been implicated as causative factors, but have not 
consistently been shown to be important risk factors [7]. 
Soft tissue calcification has also been associated with 
vitamin D use in children. Calciphylaxis can occur within 
the first year of hemodialysis treatment. Patients with 
end-stage renal disease are susceptible to a variety of 
calcification vasculopathies. Calciphylaxis can occur both 
locally and systemically. Around 1% of all patients with 
end-stage renal disease have systemic calciphylaxis when 
the calcium phosphate product exceeds 70 mg/L [12].
Calciphylaxis causes mural calcification and intimal 
fibrosis of medium and small arteries. Ischemia second-
ary to calciphylaxis may result in a wide range of end-
stage organ damage and most commonly presents as 
painful, violaceous mottled maculopapular lesions that 
can progress to plaque-like or nodular lesions. Death 
occurs in up to 60% of cases [11]. The leading cause of 
death is sepsis from infected necrotic skin lesions, 
although death due to internal organ failure has been 
reported. More subtle presentations can also be seen 
manifesting as hardened subcutaneous non-ulcerating 
plaques [7,13–15]. The pathogenesis of calciphylaxis 
is unknown [2]. It is suggested that chronic renal failure 
and/or parathyroidism results in high serum calcium 
and phosphate levels which precipitate in the small and 
medium arteries. Intimal proliferation and endovascular 
fibrosis with calcification cause the vessel lumens to 
narrow. These pathological changes can only be identi-
fied with a biopsy. Bone scan has been suggested in lieu 
of biopsy. Refractory infections are known complica-
tions of calciphylaxis [16].
As the lesion progresses, the site becomes necrotic 
with the formation of an eschar. Hard papules are pal-
pable as a result of calcium deposits in the subcutaneous 
tissue [11]. Lesions generally occur in areas that are 
adipose rich, and are thus more prevalent in women. 
Large adipose deposits are often poorly supplied by 
local blood flow. The disease process tends to spare the 
visceral vasculature, unlike atherosclerosis.
The prognosis in patients with calciphylaxis is not 
good. The cause of death is mainly due to refractory 
sepsis from wound infection. This disorder is often elusive 
because it presents like many other more common 
disorders [17].
Evidence-based treatment for this disorder is scarce 
because of the limited number of cases. It has also been 
reported in patients with primary hyperparathyroidism, 
advanced liver disease treated with albumin infusion 
and prednisone, Crohn’s disease, and long-term use of 
vitamin D supplements. Treatment options for calciphy-
laxis are palliative. However, controlling hypercalcemia, 
hyperphosphatemia and hyperparathyroidism may slow 
the disease process [18]. One can also eliminate vitamin D 
supplements, reduce dietary calcium and phosphate, 
and substitute sevelamer hydrochloride for calcium-
based phosphate binders. Parathyroidectomy may be 
beneficial if performed at the time of initial sepsis. 
However, at 8 months, the mortality rate was similar to 
that in patients who had not undergone parathyroidectomy. 
Other suggested treatment strategies include hyperbaric 
oxygen, tissue plasminogen activator, sodium thiosul-
fate, and bisphosphonates [10,19,20]. Preventive mea-
sures include weight loss, diet modification and careful 
attention to skin trauma. Patients on dialysis may benefit 
from zero-calcium and phosphorous solutions.
Skin lesions are characteristically superficial, black 
or violaceous. The relation between calciphylaxis 
and refractory infection is known. In our case, we report 
concomitant severe rapidly developing multiple non-
healing skin ulcers and C. tropicalis fungemia. The 
question that is raised is, “Does calciphylaxis predispose 
to C. tropicalis fungemia by an unknown mechanism 
or is C. tropicalis fungemia associated with the malig-
nant presentation of calciphylaxis-induced skin ulcer as 
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reported in our case report?” Interestingly, there are 
previous case reports of malignant skin ulcers secondary 
to calciphylaxis among bacteremic patients [16]. Further 
investigation is required before the above question can 
be answered. One theoretical explanation for the pos-
sible role of Candida fungemia in predisposing to 
malignant presentation of calciphylaxis-induced skin 
ulcer is that it functions as a nidus for calcium phosphate 
deposition.
Calciphylaxis-induced skin ulcer may potentially 
predispose a patient to various infections; in our case, 
these were C. tropicalis fungemia, vancomycin-resistant 
enterococcus and A. baumannii wound infection. Calci-
phylaxis is an uncommon necrotizing skin disease that 
mainly affects patients with chronic renal failure; it is 
associated with high mortality and morbidity rates. The 
mechanisms of this disease remain unclear. In the major-
ity of cases, diagnosis is established based on clinical 
data. Deep-tissue biopsy can confirm the diagnosis of 
calciphylaxis but has a high rate of complications. Early 
recognition and treatment are warranted. Despite aggres-
sive treatment regimens, calciphylaxis continues to be 
associated with high mortality.
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